|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000038306 |
|
最近更新日期: Date of Last Refreshed on: |
2020-09-17 06:29:21 |
|
注册时间: Date of Registration: |
2020-09-16 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
腹腔镜脾切断流术作为肝硬化门静脉高压出血二级预防中一线治疗的价值:一项前瞻性、多中心、随机对照研究 |
|
Public title: |
Laparoscopic splenectomy as a first-line treatment for secondary prevention of portal hypertension hemorrhage in patients with liver cirrhosis: a prospective, multicenter, randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
腹腔镜脾切断流术作为肝硬化门静脉高压出血二级预防中一线治疗的价值:一项前瞻性、多中心、随机对照研究 |
|
Scientific title: |
Laparoscopic splenectomy as a first-line treatment for secondary prevention of portal hypertension hemorrhage in patients with liver cirrhosis: a prospective, multicenter, randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张伟杰 |
研究负责人: |
王卫东 |
|
Applicant: |
Weijie Zhang |
Study leader: |
Weidong Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 18823482622 |
研究负责人电话: Study leader's telephone: |
+86 13702835586 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zwjie812@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wangweidong1968@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省佛山市顺德区伦教街道荔村甲子路1号 |
研究负责人通讯地址: |
广东省佛山市顺德区伦教街道荔村甲子路1号 |
|
Applicant address: |
1 Jiazi Road, Lunjiao, Shunde District, Foshan, Guangdong, China |
Study leader's address: |
1 Jiazi Road, Lunjiao, Shunde District, Foshan, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南方医科大学顺德医院(佛山市顺德区第一人民医院) |
||
|
Applicant's institution: |
The Southern Medical University Shunde Hospital (Shunde First People's Hospital, Foshan) |
||
|
研究负责人所在单位: |
南方医科大学顺德医院(佛山市顺德区第一人民医院) |
||
|
Affiliation of the Leader: |
The Southern Medical University Shunde Hospital (Shunde First People's Hospital, Foshan) |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
科研伦审20190439 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南方医科大学顺德医院(佛山市顺德区第一人民医院)医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of the Southern Medical University Shunde Hospital (Shunde First People's Hospital, Foshan) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 |
||
|
伦理委员会联系人: |
龙兆麟 |
||
|
Contact Name of the ethic committee: |
Zhaolin Long |
||
|
伦理委员会联系地址: |
广东省佛山市顺德区伦教街道荔村甲子路1号 |
||
|
Contact Address of the ethic committee: |
1 Jiazi Road, Lunjiao, Shunde District, Foshan, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
南方医科大学顺德医院(佛山市顺德区第一人民医院) |
||||||||||||||||||||||
|
Primary sponsor: |
the Southern Medical University Shunde Hospital (Shunde First People's Hospital, Foshan) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省佛山市顺德区伦教街道甲子路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1 Jiazi Road, Lunjiao, Shunde District, Foshan, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南方医科大学顺德医院临床研究启动计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Clinical Research Start-up Project of Shunde Hospital of Southern Medical University |
||||||||||||||||||||||
|
Target disease: |
Cirrhotic portal hypertension |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探讨HVPG指导下腹腔镜选择性贲门周围血管离断术+脾切除术对肝硬化门静脉高压症食管-胃底静脉曲张破裂出血二级预防的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of laparoscopic splenectomy guided by HVPG in the secondary prevention of esophageal and gastric variceal bleeding in cirrhotic portal hypertension. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1) 年龄18~75岁,性别不限; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Aged 18 to 75 years old male and female; (2) the patients with cirrhosis and portal hypertension were diagnosed clinically and / or pathologically; (3) having a history of esophageal and gastric variceal bleeding (black stool, hematemesis, etc.) and never receiving endoscopic treatment; (4) detecting HVPG ≥ 16mm Hg after admission; (5) Child-Pugh grade A or B of liver function; (6) ECOG score ≤ 2 or KPS score ≥ 60; (7) voluntarily participate in the study, agree to cooperate with the researcher for data collection, and sign the informed consent. |
||||||||||||||||||||||
|
排除标准: |
(1) 妊娠及哺乳期妇女; (2) 患有或可疑肝癌、胆管癌等恶性肿瘤; (3) 严重凝血障碍 (4) 大量腹水; (5) 肝功能Child-Pugh分级C级; (5) 不适于或不愿意接受行HVPG检测患者; (6) 研究者认为不适合参与研究的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) pregnant and lactating women; (2) malignant tumors with or suspected liver cancer, bile duct cancer, etc.; (3) severe coagulation disorder; (4) massive ascites; (5) Child-Pugh grade C of liver function; (6) patients who were unsuitable or unwilling to undergo HVPG testing; (7) other situations that the researchers considered unsuitable to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-01-01 00:00:00至 To 2021-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2019-01-01 00:00:00 至 To 2020-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由主要负责人采用随机表产生随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The use of random tables to generate random sequences by the principal responsible person |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验结束后上传原始数据到本网站 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
he original data will be Upload to this web site after the trial |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
试验记录 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
record |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |